Compare VTS & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VTS | CRMD |
|---|---|---|
| Founded | 2014 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 752.5M | 618.2M |
| IPO Year | 2022 | 2009 |
| Metric | VTS | CRMD |
|---|---|---|
| Price | $18.32 | $8.06 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $20.00 | $14.83 |
| AVG Volume (30 Days) | 490.7K | ★ 881.7K |
| Earning Date | 05-04-2026 | 05-11-2026 |
| Dividend Yield | ★ 11.91% | N/A |
| EPS Growth | N/A | ★ 780.00 |
| EPS | N/A | ★ 2.04 |
| Revenue | $273,989,000.00 | ★ $311,709,000.00 |
| Revenue This Year | $5.48 | $0.30 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $3.79 |
| Revenue Growth | 13.22 | ★ 617.03 |
| 52 Week Low | $17.22 | $6.13 |
| 52 Week High | $27.15 | $17.43 |
| Indicator | VTS | CRMD |
|---|---|---|
| Relative Strength Index (RSI) | 48.16 | 63.56 |
| Support Level | $17.39 | $6.14 |
| Resistance Level | $20.13 | $8.53 |
| Average True Range (ATR) | 0.52 | 0.30 |
| MACD | 0.11 | 0.04 |
| Stochastic Oscillator | 56.27 | 94.43 |
Vitesse Energy Inc is an independent energy company focused on returning capital to stockholders through owning interests as a non-operator in oil and natural gas wells. It is engaged in the acquisition, development, and production of non-operated oil and natural gas properties in the United States that are generally operated by oil companies and are in the Williston Basin of North Dakota and Montana with limited operations. The company also have properties in the Central Rockies, including the Denver-Julesburg Basin and the Powder River Basin.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.